Biophysical and Stability Characterization of Antibody-Drug Conjugates

Antibody-Drug Conjugates (ADCs) are a rapidly growing class of oncology therapeutics wherein a potent cytotoxic drug is conjugated to the antibody molecule. The impact of drug conjugation on the antibody's conformation needs to be evaluated. Additionally, the drug conjugation can also affect various physical properties of the antibody molecule which in turn can affect its stability and aggregation propensity. This presentation summarizes results from our study on aggregation of a lysine-conjugated ADC and its unconjugated mAb under accelerated heat and agitation stresses. Additionally, we also highlight spectroscopic and DSC based analytical approaches that can be used to detect subtle differences between the ADC and mAb.

Speakers

Guest Presenter: Aditya Gandhi
Aditya Gandhi graduated in 2010 from University of Mumbai, India with a bachelor’s degree in Pharmacy. He then earned a master’s degree in Industrial Pharmacy from St. John’s University, New York. With a keen interest in biotherapeutics, Aditya joined the Pharmaceutical Sciences program at the University of Colorado in August 2013 where he works on in-depth characterization of physical stability and aggregation of therapeutic proteins.

More Information

• Who should attend?
  Anyone interested in biopharmaceuticals, especially antibody-based therapeutics
• What will you learn?
  The biophysical properties of ADCs, some analytical considerations for ADCs, and the impact of drug conjugation on protein aggregation